Trevi Therapeutics, Inc. (TRVI) Deep Dive Video

Summary

Trevi offers a highly asymmetric, single-asset biotech opportunity: Haduvio could define a new chronic cough market, but the investment case hinges almost entirely on pivotal clinical success.

View TRVI stock page · Read the TRVI research report

Loading the video player…